喻兆阳;薛慧颖;

• 1:华中科技大学同济医学院附属同济医院药学部
• 2:华中科技大学同济医学院药学院

摘要(Abstract)：

使用尾静脉高压注射基因转染技术将不同质量AKT基因转染至FVB/N小鼠肝脏,探讨不同AKT表达量对AKT/Ras介导的小鼠肝癌发生发展的影响.随机将6周龄雌性FVB/N小鼠分为3组,对照组尾静脉高压注射空载体质粒,模型组A尾静脉高压注射75μg AKT、75μg Ras质粒,模型组B尾静脉高压注射150μg AKT质粒、75μg Ras质粒.并在小鼠造模后第2、4、6周处死小鼠,记录体质量并取肝脏组织称肝质量,检测血清ALT、AST水平,观察并记录肝癌生长情况.最后检测小鼠肝脏AKT、p-AKT、FASN和Ras的表达情况,并检测3组小鼠肝脏脂肪累积变化情况.结果显示,在2周时模型组A与模型组B小鼠血清中ALT和AST水平均呈不同程度的升高,提示有肝功能损伤,但两组间无显著差异.两模型组小鼠肝脏均形成肿瘤,但模型组A小鼠体质量、肝脏质量、肿瘤结节数量和大小明显低于模型组B小鼠.AKT基因可明显增加小鼠肝脏组织FASN的表达,并提高小鼠肝脏组织脂质累积量,促进小鼠肝癌的发生和发展.

关键词(KeyWords)： 肝细胞癌;高压注射转染技术;AKT基因;Ras基因;脂质累积

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助项目(81201553);; 华中科技大学自主创新研究基金(514/5003514011)

作者(Authors): 喻兆阳;薛慧颖;

参考文献(References)：

• [1]ALLEMANI C,MATSUDA T,DI CARLO V,et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
• [2]FITZMAURICE C,AKINYEMIJU T F,AL L F,et al.Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted Life-years for 29 cancer groups,1990 to 2016:a systematic analysis for the global burden of disease study[J].JAMA Oncol,2017,3(4):524-528.
• [3]ZHANG T,HUANG J,YI Y,et al.Akt serine/threonine kinase 1 regulates de novo fatty acid synthesis through the mammalian target of rapamycin/sterol regulatory element binding protein 1 axis in dairy goat mammary epithelial cells[J].J Agric Food Chem,2018,66(5):1197-1205.
• [4]刘清南,戴志兵,袁中华,等.Adipophilin通过PI3K/Akt通路促进细胞内脂质蓄积[J].中国病理生理杂志,2018,34(7):1189-1194.
• [5]喻兆阳,何阳,罗伟,等.AKT基因介导的小鼠非酒精性脂肪肝模型的建立[J].华中科技大学学报(医学版),2016(2):170-175.
• [6]JAFARI N,DRURY J,MORRIS A J,et al.De novo fatty acid synthesis-driven sphingolipid metabolism promotes metastatic potential of colorectal cancer[J].Mol Cancer Res,2019,17(1):140-152.
• [7]MASHIMA T,SEIMIYA H,TSURUO T.De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy[J].Br J Cancer,2009,100(9):1369-1372.
• [8]MENENDEZ J A,LUPU R.Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis[J].Nat Rev Cancer,2007,7(10):763-777.
• [9]CHARETTE N,LECLERCQ I A.Why should the gastroenterologist bother about obesity?An oncologic point of view[J].Acta Gastroenterol Belg,2010,73(4):504-509.
• [10]SIEGEL A B,ZHU A X.Metabolic syndrome and hepatocellular carcinoma:two growing epidemics with a potential link[J].Cancer,2009,115(24):5651-5661.
• [11]李胜男,张海英,孙千惠,等.水流动力学注射对小鼠肝损伤及肝脏的自然修复作用[J].吉林大学学报(医学版),2018(02):275-280.
• [12]马聪,张玉龙,周欠欠,等.高压水动力法建立肝特异性白细胞介素-6报告基因小鼠模型[J].军事医学,2017(4):269-272.
• [13]CHEN X,CALVISI D F.Hydrodynamic transfection for generation of novel mouse models for liver cancer research[J].The American Journal of Pathology,2014,184(4):912-923.
• [14]HO C,WANG C,Mattu S,et al.AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1),FOXM1 (forkhead box M1)/SKP2,and c-Myc pathways[J].Hepatology,2012,55(3):833-845.
• [15]ALLEMANI C,MATSUDA T,DI CARLO V,et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
• [16]SPANGENBERG H C,THIMME R,BLUM H E.Targeted therapy for hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol,2009,6(7):423-432.
• [17]KUDO M.Targeted and immune therapies for hepatocellular carcinoma:predictions for 2019 and beyond[J].World J Gastroenterol,2019,25(7):789-807.
• [18]ZHU J,YIN T,XU Y,et al.Therapeutics for advanced hepatocellular carcinoma:recent advances,current dilemma,and future directions[J/OL].J Cell Physiol,2019.DOI10.1002/jcp.28048.
• [19]YAM J W,WONG C M,NG I O.Molecular and functional genetics of hepatocellular carcinoma[J].Front Biosci (Schol Ed),2010,2:117-134.
• [20]SIEGEL A B,ZHU A X.Metabolic syndrome and hepatocellular carcinoma:two growing epidemics with a potential link[J].Cancer,2009,115(24):5651-5661.
• [21]MASHIMA T,SEIMIYA H,TSURUO T.De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy[J].Br J Cancer,2009,100(9):1369-1372.
• [22]ZAIDI N,LUPIEN L,KUEMMERLE N B,et al.Lipogenesis and lipolysis:the pathways exploited by the cancer cells to acquire fatty acids[J].Prog Lipid Res,2013,52(4):585-589.
• [23]CALDWELL S H,CRESPO D M,KANG H S,et al.Obesity and hepatocellular carcinoma[J].Gastroenterology,2004,127(5 Supl 1):S97-S103.
• [24]CALLE E E,RODRIGUEZ C,WALKER-THURMOND K,et al.Overweight,obesity,and mortality from cancer in a prospectively studied cohort of U.S.adults[J].N Engl J Med,2003,348(17):1625-1638.
• [25]ZONCU R,EFEYAN A,SABATINI D M.mTOR:from growth signal integration to cancer,diabetes and ageing[J].Nat Rev Mol Cell Biol,2011,12(1):21-35.
• [26]KRYCER J R,SHARPE L J,LUU W,et al.The Akt-SREBP nexus:cell signaling meets lipid metabolism[J].Trends Endocrinol Metab,2010,21(5):268-276.
• [27]NABARRA B,MULOTTE M,CASANOVA M,et al.Ultrastructural study of the FVB/N mouse thymus:presence of an immature epithelial cell in the medulla and premature involution[J].Dev Comp Immunol,2001,25(3):231-243.
• [28]GEDALY R,ANGULO P,HUNDLEY J,et al.PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation[J].J Surg Res,2012,176(2):542-548.
• [29]BARTEL K,WINZI M,ULRICH M,et al.V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy[J].Oncotarget,2017,8(6):9476-9487.
• [30]LI L,ZHAO G D,SHI Z,et al.The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC[J].Oncol Lett,2016,12(5):3045-3050.